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ABSTRACT 
 
Spinocerebellar ataxia type 1 (SCA1) is one of nine Polyglutamine Diseases caused 
by CAG expansion in the coding region of the corresponding gene. In SCA1, CAG 
expanded repeats cause an abnormally long glutamine tract in ATXN1 protein and 
trigger a gain of function pathogenic mechanism that leads to a progressive 
neurodegenerative disorder. The brain regions primarily affected are the cerebellum 
and the brainstem. Previous studies reported that insulin sensitivity and insulin 
secretion are abnormal in SCA1 patients. We hypothesize that expression of mutant 
ATXN1 impairs glucose metabolism and use multiple approaches to test this 
hypothesis using mice and Drosophila disease models. Gene expression analyses 
in SCA1 mice and flies suggest glucose uptake deficiency in neuronal cells. 
Confirming these results, positron emission tomography imaging suggests lower 
glucose level in the cerebellum of SCA1 transgenic mice. Metabolomic (NMR) 
analyses in SCA1 fly neurons reveal a decrease in glucose metabolism metabolites. 
We carried out a genetic screen in Drosophila of all genes encoding glycolytic 
enzymes for potential modifier genes of SCA1 pathogenesis. We found that 
reducing the activity of glycolytic genes ameliorates neurodegeneration in the SCA1 
Drosophila model. Further mechanistic studies indicate suppression of ATXN1-
induced neurodegeneration is mediated by reduced steady-state levels of mutant 
ATXN1 protein. Together these data suggest that glucose metabolism impairments 
contribute to SCA1 pathogenesis and reveal new therapeutic approaches to 
decrease ATXN1 neurotoxicity.  
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RESUMEN 
 
La Ataxia Espinocerebellar Tipo 1 (SCA1) es una de las nueve Enfermedades 
Poliglutamínicas que se caracterizan por la expansión del triplete CAG en la 
región codificante del gen correspondiente. En SCA1, la expansión de las 
repeticiones de CAG causan un tracto de Glutaminas anormalmente largo en la 
proteína ATXN1 provocando una mutación de ganancia de función que provoca 
la aparición de neurodegeneration con carácter progresivo. Las regiones 
primariamente afectadas en SCA1 son el cerebelo y el troco cerebral. Estudios 
previos revelaron que pacientes con SCA1 desarrollan un aumento de 
resistencia a la insulina. Por lo cual, nosotros hipotetizamos que la expresión de 
ATXN1 mutante causa defectos en el metabolismo de la glucosa. Para 
corroborar esta hipótesis utilizamos diversas técnicas usando Drosophila y 
ratones como modelos de la enfermedad. Análisis de expresión genómica en 
moscas y ratones de SCA1 sugieren la deficiencia en el transporte de la 
glucosa en neuronas. Estos resultados fueron confirmados por tomografía de 
emisión de electrones en ratones transgénicos de SCA1. Análisis 
metabolómicos en moscas de SCA1 revelaron una reducción en metabolitos 
que participan en el metabolismo de la glucosa. Además llevamos a cabo un 
rastreo genético de genes que codifican enzimas glicolíticas para la búsqueda 
de modificadores genéticos. Este estudio reveló que la falta de función de las 
enzimas glicolíticas aminora la neurodegeneración reduciendo los niveles de la 
proteína mutante ATXN1. Todos estos datos sugieren que la patogenia de 
SCA1 causa defectos en el metabolismo de la glicólisis abriendo la puerta a 
nuevos avances terapéuticos para disminuir la neurotoxicidad producida por 
ATXN1. 
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1. INTRODUCTION 
 
1.1. POLYGLUTAMINE DISEASES 
 
Spinocerebellar ataxia type 1 is one of the nine dominant inherited autosomal 
neurodegenerative diseases caused by the CAG expansion in the coding region of 
the gene encoding the protein ATXN1 (Zoghbi and Orr 1995). This group of 
neurological disorders, collectively known as Polyglutamine Diseases, includes 
Huntington disease (HD), Spinal and Bulbar Muscular Atrophy (SBMA), 
Dentatorubral-Pallidoluysian Atrophy (DRPLA), and the Spinocerebellar Ataxias 
(SCAs) 1, 2, 3, 6, 7 and 17 (Table 1). CAG expanded repeats cause an abnormally 
long glutamine tract in the disease-causing protein, and trigger a gain of function 
mutation of the protein that leads a progressive neurological disorder characteristic 
PolyQ 
disease 
Gene / 
Protein Locus 
Fly homolog 
gene 
PolyQ expansion 
Normal Pathological 
HD 
SCA1 
SCA2 
SCA3 
SCA6 
SCA7 
SCA17 
SBMA 
DRPLA 
HTT 
ATXN1 
ATXN2 
ATXN3 
CACNA1A 
ATXN7 
TBP 
AR 
ATN1 
4p16.3 
6p23 
12q24 
14q24-q31 
19p13 
3p21–p12 
6q27 
Xq11-q12 
12p13 
Htt 
Atx-1 
Atx2 
No homolog 
Ca-alpha1D 
No homolog 
Tbp 
No homolog 
Gug 
6–35 
6–44 
14–32 
12–40 
4–18 
7–18 
25–43 
6–36 
3–38 
36–121 
39–83 
34–77 
62–86 
21–30 
38–200 
45–63 
38–62 
49–88 
Table1. List of  Polyglutamine Diseases. HD = Huntington’s Disease; SCA = 
Spinocerebellar Ataxia; SBMA = Spinal Bulbar Muscular Atrophy; DRPLA = 
Dentatorubropallidoluysian Atrophy; HTT (Htt) = Huntingtin; ATXN1/2/3/7 = Ataxin-
1/2/3/7; CACNA1A = Calcium Channel, Voltage-Dependent, P/Q Type, Alpha 1A 
Subunit; TBP (Tbp) = TATA-binding protein; AR = Androgen receptor; ATN1 = atrophin-
1; Atx-1 = Ataxin 1; Atx2 = Ataxin 2; Ca-alpha1D = Ca2+-channel protein α1 subunit D; 
Gug = Grunge.  (Bauer and Nukina 2009) 	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of these diseases (Gatchel 2005). Although the number of CAG triplet repeats 
necessary to trigger pathogenesis differs between polyQ disorders (Table 1), the 
length of the repeat expansion positively correlates with disease severity and age of 
onset. (H. Orr 2001, Gatchel 2005).  
 
Polyglutamine proteins are widely expressed in the nervous system and it is 
still controversial why there is differential neuronal vulnerability for each polyQ 
disease. For example in HD the neurodegeneration is primarily observed in the 
striatum (Ginovart 1997), whereas SCA’s are characterized by cerebello-olivary 
atrophy (Klockgether 2008). 
 
A prominent neuropathological feature observed in most of these disorders 
is the age-dependent formation of cytoplasmic and/or intranuclear accumulation of 
aggregated proteins inside neurons that contain the polyQ protein and other 
proteins involved in the ubiquitin–proteasome and molecular chaperone systems 
(Ross 1997, DiFiglia 1997). Nuclear aggregates can abnormally interact with nuclear 
proteins and lead to gene transcriptional dysregulation and neuropathology (Li 
2007). Cytoplasmic accumulation can alter axonal transport disrupting synaptic 
function and glutamate release (Li 2003). 
 
Although these studies suggested that both nuclear and cytoplasmic 
aggregates of polyQ proteins cause pathogenesis, these aggregates may also 
protect by sequestering toxic oligomeric species (Saudou 1998, Lasagna-Reeves 
2015). 
 
The polyQ inclusions usually appear in the affected brain regions, thereby in 
the case of SCA1 intracellular aggregations are observed largely in the Purkinje cells 
(PC) and granular cells.  
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1.2. ATAXIA SPINOCEREBELLAR TYPE 1 
 
SCA1 is a neurodegenerative disorder characterized by progressive 
dysfunction that affects Purkinje cells in the cerebellum, cells of the inferior olive in 
the cerebellum cortex and neurons within brainstem cranial nerve nuclei (Zoghbi 
and Orr 1995) (Fig1). SCA1 is caused by the CAG expansion in the ATXN1 gene, 
which is localized in the short arm of chromosome 6 (Zoghbi and Orr 1995). The 
gene was cloned in 1993 by Dr. Huda Zoghbi (Department of Molecular and 
Human Genetics, Baylor College of Medicine, Houston, United States) and Dr. 
Harry Orr (Institute for Translational Neuroscience, University of Minnesota, 
Minnesota, United States) and found to encode a novel protein designated ATXN1 
(ataxin-1) (Orr 1993). Approximately 1-2 in 100,000 people will develop SCA1, 
however the frequency varies considerably based on geographical location and 
ethnic background (data from National Ataxia Foundation). 
Figure 1.  Brain  affected areas in  SCA1 disease and cerebel lum h isto logy. 
Cerebellum and brain stem are the mainly affected areas in SCA1 patients. Cells of the 
inferior olive and Purkinje cells are localized in the cerebellum. Cranial nerve nucleus is 
situated in the brainstem. A. Transverse section of a cerebellar folium. Purkinje cells 
dysfunction is crucial for SCA1 pathology. Cerebellum histology drawing was published 
in “Anatomy of the Human Body” (1918) by Henry Vandyke Carter and Henry Gray.  
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The cerebellum is a region of the brain (Fig 1) that has an important role in 
coordination, precision, and accurate timing of body movement; therefore it is 
crucial for a precise motor control. It is also involved in some cognitive function 
such as attention and language. The cranial nerve nucleus, which is a collection of 
neurons in the brain stem (Fig. 1), also plays an important role in motor activity. 
Thus since SCA1 causes neurodegeneration of the cerebellum and cranial nerve 
nucleus, most clinical features are related to the motor control. Among these 
features we find ataxia, spasticity, ophthalmoparesis, slow saccades, and cognitive 
impairment such as impairment in visual-spatial perception and attention (Zoghbi 
and Orr, 1995, Ma 2014). With the progression of the disease other symptoms 
emerge such as dystonia, tongue atrophy, dysphagia, dysphonia, deep sensory 
loss, etc (Zoghbi and Orr, 1995). At present there is no treatment for SCA1. The 
medication is indicated to alleviate the symptoms of the disease. 
 
ATXN1 normal alleles contain between 6 and 39 CAG repeats located within 
exon 8 (Orr 1993). The pathogenesis appears when the CAG expansion of the 
glutamine-encoding CAG tract exceeds 40 repeats (Chung 1993). The typical age 
of onset is in the third or fourth decade with variations depending on repeat length. 
Anticipation refes to the observation that CAG repeats can expand further during 
male germline transmission, causing earlier onset and increased severity of the 
disease in successive generations (Zoghbi and Orr 2009). 
 
Mutant ATXN1 tends to accumulate in the nucleus to form insoluble 
aggregates (Cummings 1998). The primary pathogenic role of these structures is 
still unclear since neurons with inclusions are not always the most vulnerable to 
death. Immunohistochemical staining of aggregates reveals components of the 
proteasome system and ubiquitin, which are involved in protein turnover. These 
findings suggest that impairments in proteasome function likely contribute to the 
pathogenesis of the disease (Cummings 1998, Taroni 2004) (Fig 2). 
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1.2.1. Ataxin-1 Protein (ATXN1) 
 
Genetic and molecular evidences indicate that in SCA1, neurodegeneration 
is mainly caused by a gain-of-function mechanism in the ATXN1 protein. Evidences 
includes null Atxn1 mice, which are viable and fertile, and do not develop ataxia or a 
neurodegeneration phenotype (Matilla 1998). Also it is important to point that 
abnormally high levels of wild-type ATXN1 can cause degenerative phenotypes 
comparable to those caused by the expression of the expanded protein 
(Fernandez-Funez, 2000). However other data suggest that partial loss of ATXN1 
function might contribute to pathogenesis. For example studies in mice show that 
deletion of the wild type Atxn1 gene enhances SCA1 pathogenesis, and an 
Figure 2. Proposed pathogenic mechanisms of ATXN1. Cerebellum and brainstem 
are the major areas affected in SCA1 (1,2). The mutant ATXN1 gene contains expanded 
CAG repeats which are transcribed (3) and translated (4) into long polyglutamine tracks. 
Due to the polyQ expansion, ATXN1 acquires an aberrant conformation, which can be 
corrected by molecular chaperones (5 ). Misfolded ATXN1 protein may be ubiquitinated (Ub) 
(6) and degraded via the proteasome (7 ). ATXN1 protein is imported into the nucleus (8) 
where it potentially form aggregates. In addition to ATXN1 protein, aggregates contain 
transcription factors, ubiquitin, and other proteasome components. (Adapted from Taroni, 
2004) 
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increase of Ataxin 1-Like gene, which is a conserved paralog of ATXN1, ameliorates 
the neurodegeneration. (Crespo-Barreto 2010) 
 
The polyQ expansion is necessary but not sufficient to cause toxic events 
(Fernandez-Funez, 2000). Studies revealed important domains in ATXN1 protein 
that are critical for SCA1 pathogenesis including the AXH domain, the nuclear 
localization signal (NLS),and a single serine residue localized at position 776 (S776) 
(Fig. 3). In fact, the overexpression of polyglutamine-expanded ATXN1 lacking any 
of these domains ameliorates Purkinje cell degeneration reducing pathogenesis 
events in mice (Klement 1998, Emamian 2003, Tsuda 2005).  
 
The AXH domain is a 130 amino acids-long protein motif, which forms an 
oligonucleotide-binding fold and is important for dimerization of ATXN1, for protein-
protein interaction and RNA binding (de Chiara 2003). Proteins already identified 
that bind to ATXN1 via interactions with its AXH domain include Capicua (CIC), 
which is a transcriptional repressor whose repressing activity and levels are 
modulated by ATXN1 (Lam 2006). Also the zinc-finger transcription factor 
Senseless (Sens) in Drosophila and its mammalian homolog Gfi-1 interact with 
Figure 3.  Protein  domains cr it ical for ATXN1 funct ion and SCA1 
pathogenesis. The functional domains are indicated as purple boxes. This protein 
corresponds to ATXN1 wild-type allele with 816 amino acids and 30 glutamine repeats. 
Wild-type ATXN1 contains 6-40 glutamines, while mutant ATXN1 may contain from 39 
to 83 glutamines. The AXH domain has the ability to interact with other proteins such as 
Capicua and Gfi-1. The NLS domain targets ATXN1 to the nucleus. Finally, the residue 
of the NLS, Ser776, is an important site of phosphorylation in ATXN1. (Adapted from 
Zoghbi and Orr, 2008) 
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ATXN1 through the AXH domain and this interaction may contribute to the selective 
vulnerability of Purkinje cells observed in SCA1 (Tsuda 2005).  
 
 ATXN1 contains a nuclear localization signal (NLS) close to its C-terminus. 
To study the role of the NLS, mice were generated expressing ATXN1 with 82 CAG 
repeats and a mutated NLS. This mutant ATXN182Q accumulated within the 
cytoplasm of Purkinje cells and did not form aggregates. In addition PC from these 
mice did not show cell histopathology such as nuclear inclusions or degeneration. 
Furthermore they did not display an abnormal neurological phenotype (Klement 
1998). 
 
 Phosphorylation is an important mechanism to regulate protein activity. 
Examination of all the ATXN1 residues susceptible to be phosphorylated lead to the 
finding that serine 776 (S776) was phosphorylated (Emamian 2003). To study the 
effect of this phosphorylation, S776 was replaced with a residue of alanine to 
prevent phosphorylation and its effect was studied in cell and mouse SCA1 models. 
In both cases the pathogenesis was considerably reduced, indicating that S776, 
and possibly protein conformation, have key roles in the toxicity generated by 
mutant SCA1 (Emamian 2003).  
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1.3. ANIMAL MODELS OF NEURODEGENERATIVE DISEASES 
 
 Neurodegenerative disorders are characterized by a gradual loss of the 
neuronal cell population. This leads to cognitive, behavioral and/or physical 
impairments. The limitation of human trials is the difficulty in analyzing the cellular 
pathology for greater understanding of the disease. Thus, animal models for 
different neurodegenerative diseases models have been developed to reproduce 
the largest possible number of features of these disorders in simpler systems. 
 
 
1.3.1. Drosophi la model 
 
Drosophila has proved to be an excellent model for genetic studies in human 
neurological disorders due to several advantages: 
• Enables the expression of human genes, both in mutant and wild-type forms. 
• Allows study of gain or loss of function mutations in human homolog genes. 
• Appropriate for large-scale genetic screening. 
• Simpler fly genome compared to the complex human genomic organization. 
• Lack of many redundant genes in flies. 
• Availability of versatile genetic manipulation procedures. 
• Over 75% of human genes are conserved in Drosophila and importantly, cell 
biology mechanisms are highly conserved such as neuronal connectivity, 
regulation of gene expression, cell signaling and cell death (Rubin 2000). 
 
The GAL4/UAS system (Fig 4) (Brand and Perrimon 1993) allows to control of 
transgene expression levels and targeting to different cell types, including specific 
populations of neurons. This system also provides a temporal targeted gene 
expression strategy in Drosophila (Brand and Perrimon 1993). 
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1.3.1.1. ATXN182Q Drosophila model 
 
 To carry out genetic studies of SCA1, a transgenic Drosophila was created 
by Dr. Juan Botas (Department of Molecular and Human Genetics, Baylor College 
of Medicine, Houston, Texas 77030, USA) laboratory 15 years ago (Fernandez-
Funez 2000). This SCA1 fly model contains an insertion of the full-length human 
ATXN1 gene with 82 CAG repeats, which encodes an ATXN1 protein with a 82 aa-
long polyglutamine tract. The level of the transgene expression is controlled using 
the UAS/GAL4 system (Fig. 3).  
 
Figure 4. UAS-GAL system. This binary system is used to target gene expression in 
a specific cell population such as neurons. The gene to be expressed is placed 
downstream of the yeast upstream activating sequence (UAS) element. In the absence 
of the yeast GAL4 transcription factor, the UAS-GeneA transgene remains silent. To 
activate transcription of the UAS-GeneA, flies that contain this construct (UAS-GeneA) 
are mated with flies carrying the Promoter-GAL4 driver. The resulting F1 progeny larvae 
and adults express the GeneA (Brand and Perrimon, 1993).  
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To serve as a good disease model, the transgenic flies must recapitulate the 
main pathogenic features of the disease in humans. These flies exhibited the main 
characteristics of the SCA1 features in humans such as neurotoxicity, the pattern of 
SCA1 progression and the presence of nuclear inclusions. The expression of the 
ATXN182Q transgene in the nervous system causes a progressive reduction of cell 
bodies and axonal projections. In addition, a variety of cell types, including central 
nervous system neurons and photoreceptors, show nuclear aggregates. These 
nuclear aggregates contain ubiquitin, proteasome and Hsp70 chaperone. The 
transgenic flies also recapitulate another important feature of SCA1 pathogenesis, 
Figure 5.  Drosophi la  ATXN1 [82Q] model . (A) Strong eye phenotypes caused by 
SCA1 overexpression. 1-2, scanning electron microscope (SEM) eye images of gmr–
GAL4/+ control (1), and UAS: SCA1 82Q/+; gmr–GAL4/+ (2). Insets correspond to 
magnification of ommatidia field. 3-4, Paraffin sections (hematoxylin stain) through the 
retinas of gmr–GAL4/+ control eyes (3), and UAS: SCA1 [82Q]/+; gmr–GAL4/+ (4) 
transgenic flies at the same magnification. Flies were raised at 28.5 oC. Degeneration of 
the retina (arrow) is severe in ATXN1[82Q]-expressing flies. (B) Western blot of head 
extract shows the presence of ATXN1 in this Drosophila SCA1 model. (LaminC: loading 
control). (C) Modification of UAS: SCA1 [82Q]/+; nrv2–GAL4/+ neuronal phenotype in 
motor performance assay. Quantification of the climbing performance of flies as a 
function of age. The nervana-GAL4 (nrv2) driver was used to direct expression of the 
mutant proteins to the nervous system Flies were raised at 28.5 oC.  
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which is the positive correlation between the severity and early disease onset with 
the number of CAG repeats expansion. (Fernandez-Funez 2000).  
 
These flies were the first model used in a genetic screen for modifiers 
(suppressors and enhancers) of a neurodegenerative disease. The screen identified 
potential modifiers such as genes involved in ubiquitin-proteolytic pathways, protein 
folding/heat-shock response and genes that encode proteins containing RNA-
binding domains (Fernandez-Funez 2000).  
 
In this study, we used SCA1 transgenic flies with one of the two different 
constructs. In the first construct, the expression of ATXN182Q  is driven by the eye 
specific driver, gmr-GAL4 to cause retina degeneration (Fig 4). In the other 
construct, the expression of ATXN182Q is driven by the pan neuronal driver nrv2. To 
study the progressive neurodegeneration caused by ATXN182Q, we performed 
motor behavioral test, where we measured the ability of the fly to climb in 
successive time points (Fig. 5).  
 
A couple of years ago, a cross-species strategy was developed: combining 
forward genetic screens that targeted the levels of mutant human ATXN1 in the 
SCA1 Drosophila model and a human cell model of SCA1. The cells were 
generated from a human medulloblastoma-derived cell line, and contain a 
transgene encoding a CAG-expanded ATXN1 fused with monomeric red 
fluorescent protein (mRFP–ATXN182Q). Placing an internal ribosomal entry site (IRES) 
followed by yellow fluorescent protein (YFP)-encoding sequence downstream of the 
ATXN1 fusion sequence, allowed to detect changes in the ATXN182Q protein levels 
using the ratio of mRFP to YFP fluorescence as read-outs. We found that the 
downregulation of numerous components of the RAS-MAPK-MSK1 pathway 
suppresses neurodegeneration in SCA1 flies, and decreases ATXN1 levels in both 
cells and flies. Importantly we carried out a drug trial assay revealing new 
therapeutic approaches to decrease ATXN1 pathogenic (Park 2013).  
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1.3.2. Mus musculus model 
 
Mouse is a powerful model to study the mechanisms of neurological 
diseases and for testing potential therapies. This is due to the high conservation of 
genes between human and mouse. In addition, the ability to manipulate the mouse 
genome has been rapidly growing (Cathleen 2014). 
Technical approaches to generate neurodegenerative mouse models include 
reverse genetics (Capecchi 1989), transgenic mice (Palmiter 1985), exogenous 
transposon-transposase system (Largaespada 2009), mutagenesis using mutagen 
agents (Justice 1999), and introducing interfering RNAs (RNAi) (Tiscornia 2003). 
These techniques allow generating different types of mouse models of diseases (Fig 
6): 
• Knockout: an endogenous gene is inactivated by replacing or disrupting it with 
an artificial piece of DNA, using a mutagen or by gene editing technologies. 
• Knockdown: gene expression is downregulated, for example by RNAi. 
• Transgenic: insertion of an exogenous gene into the genome. 
• Knock-in: insertion of a protein coding cDNA sequence in a specific locus in the 
mice genome. The difference between knock-in and transgenic technology is 
that a knock-in involves a gene inserted into a specific locus. . In principle, 
knock-in mice are the best approach to generate an accurate genetic model, 
because they may guarantee accurate spatial and temporal expression patterns 
at endogenous levels.  
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1.3.2.1. SCA1 transgenic mouse model 
 
Transgenic mice were generated to gain insight of the SCA1 pathogenesis. 
They express the mutant human ATXN1 gene with an expanded CAG tract with 82 
repeats. This transgenic mouse strain is called B05. As a control (called A02), a 
normal human ATXN1 gene with 30 CAG repeats was inserted into the mouse 
genome (Burright 1995). Expression of these transgenes was directed to the 
cerebellar Purkinje cells by the driver Pcp2 (Vandaele 1991), since these cells are 
the primary site of SCA1 cerebellar pathology.  
 
To examine intergenerational stability of CAG repeats, 254 transgenic 
animals were studied and no changes in repeat size were observed (Burright 1995). 
Transgene expression levels were approximately 100-fold higher than endogenous 
Figure 6.  Types of mutated mice.  Knockout: Inactivation of an existing gene by 
replacing it or disrupting it with an artificial piece of DNA. Knockdown: Reduction of the 
expression of a gene through genetic modification or by treatment with reagents such as 
RNAi.	  Transgenic: Insertion of an exogenous gene into the genome. Knock-in: insertion of 
a protein coding cDNA sequence at a particular locus. 
	   36	  
level of ATXN1 RNAs measured by reverse transcriptase-PCR reaction (Burright 
1995). 
 
B05 mice exhibited motor performance abnormities starting at five weeks of 
age (Fig. 8), as assayed by a set of motor tests, which included footprint patterns 
assay, rotating rod, bar cross apparatus and open field test (Clark, 1997). 
Heterozygous B05 mice developed ataxia at twelve weeks of age (Fig. 7) and 
displayed an abnormal neurological phenotype, assessed by home cage behavior 
(Burright 1995, Clark 1997).  
 
The pathogenic events observed in Purkinje cells include cytoplasmic vacuolization 
(day 25), simplification of the dendritic tree (six weeks), cell loss (twelve weeks) 
shrinkage of the molecular layer (fifteen weeks) and frequent heterotopia (fifteen 
weeks) (Clark 1997) (Fig. 8). All the phenotypes and pathology progressed with age 
(Clark 1997) 
Figure 7.  B05 t ransgenic mice ataxia phenotype. B05 (+/-) mice display clear 
signs of ataxia by falling to one side when walking at the age of 30 weeks. (Burright 1995) 
	   37	  
 
1.3.2.2. SCA1 knock-in mouse model 
 
In addition to the B05 mice, which showed a phenotype associated with 
dysfunctional Purkinje cells, SCA1 knock-in mice carrying 154 CAG repeats into the 
endogenous mouse ATXN1 locus were also generated (Watase 2002). SCA1 
knock-in mice exhibited characteristic pathological features associated with SCA1 
in humans such as cognitive impairment and shorter lifespan (Watase 2002)  
 
  
Figure 8.  Behavioral  phenotype and Purk in je cel l  (PC) h istopathology in  B05 
transgen ic mice.  (A-C), rotating rod performance. (A), five-week old. (B), twelve-week-
old. (C), nineteen-week-old. (A-C), B05/+ animals showed performance improvement. (D-
F), immunohistochemical staining of cerebellar sections of SCA1 transgenic mice with 
calbindin. D, B05/+, 15 weeks old, animals showed shrinkage of the molecular layer and 
many PCs with atrophic dendritic morphology. Occasional PCs are located heterotopically 
in the molecular layer. E, B05/+ animal at 27 weeks old with increased severity compared 
to D. In addition, occasional larger hypertrophic PCs were apparent. F, A02/+ animal at 1 
year old showed normal PCs number and dendritic arborization. Scale bars: 30 mm in D–
F. B05/+ with 82 repeats. A02/+ with 30 repeats. Adapted from (Clark 1997) 
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Figure 9. Phenotypes and patho logy of knock- in  SCA1154Q/2Q mice.  (A–D), 
Immunofluorescence confocal microscopy images of 34 weeks old Sca1154Q/2Q 
cerebellums. Mutant animals (A and B) show altered cerebellar morphology compared to 
wild type mice (C and D). Staining with α-calbindin. Scale bars: 100 mm. (E and F), 
sagittal sections from the wild type (E) and mutant (F) brains (40 weeks old) showed brain 
atrophy in Sca1154Q/2Q mice. G and H, representative images of 28 weeks old mutant and 
wild-type mice. Mutant mice (G) show severe kyphosis (curvature of the spine). I and J, 
rotating rod performance. Sca1154Q/2Q animals showed impaired performance at five week-
old (I) and seven-weeks-old (J). (K-N), CA1 hippocampal neurons images from mutant 
animals. Nuclear inclusions were positive for Atxn-1 (K) and ubiquitin (L) in seven week-
old, but not for HDJ2 chaperone (M) seven week-old mice. In a 40 weeks old, most of the 
CA1 neurons are positive for HDJ-2 (N). Insets show individual CA1 neurons at higher 
magnification. Original magnification for each image was 200X. Adapted from (Watase 
2002). 
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These mice show pathological phenotypes that included: growth retardation 
(eight weeks old); muscle wasting, ataxia, and abnormal gait (twenty week-old); 
impaired performance in rotating rod (five and seven weeks old) (Fig. 9); severe 
kyphosis (curvature of the spine) accompanied by atrophy of lower limb muscles 
(30 weeks old) (Fig 9) and premature death (35 and 45 weeks old). They also show 
spatial memorial deficits assessed using the Morris water maze at five to seven 
weeks old (Watase 2002).  
 
Neuropathology studies revealed brain atrophy (Fig. 9), and redaction of 
Purkinje cell dendritic arbors with approximately 50% less fluorescence than control 
animals at 19 weeks old (Fig. 9). Nuclear inclusions of ATXN1 were observed 
starting at six weeks of age in mutant animal brains in multiple neuronal populations 
(Fig 9). In addition, the inclusions were positive for ubiquitin (7 weeks old) and 
chaperons (40 weeks old) (Watase 2002) (Fig 9). 
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1.4. GLUCOSE METABOLISM 
 
Glucose is a monosaccharide with the molecular formula C6H12O6. The name 
"glucose" comes from the Greek word gleûkos, meaning "sweet wine, must". With 
six carbon atoms, it is classified as a hexose, a sub-category of monosaccharides. 
 
Cells use glucose as a primary source of energy through aerobic respiration, 
generating biochemical energy in the form of adenosine triphosphate (ATP) (Berg 
2002). Aerobic respiration is a multi-step of catabolic reactions consisting of a 
series of biochemical steps, which include glycolysis, oxidative decarboxylation of 
pyruvate, citric acid cycle and oxidative phosphorylation. Glucose is the most 
important starting substrate for these reactions, although other nutrients can also 
be used. These compounds are catalyzed to the final product of form CO2 and 
H2O, obtaining energy mostly in the form of ATP (Berg 2002).  
 
Photoautotrophic organisms like plants synthesize glucose by 
photosynthesis using water and carbon dioxide. However, heterotrophic organisms 
are unable to perform this process and they take glucose from other organisms. 
Glucose can also be obtained from other sugars, such as fructose and galactose. 
Thus, Glucose is one of the three dietary monosaccharides, along with fructose and 
galactose, which are absorbed directly into the bloodstream during digestion. 
Another way to obtain glucose is by synthesis from non glucidic molecules, a 
process known as gluconeogenesis. There are certain glucose precursor 
molecules, such as lactate, amino acids, oxaloacetate and glycerol (Eisenstein 
1967).  
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1.4.1. Glucose uptake and glycolysis 
 
Insulin is a polypeptide hormone produced and secreted by β-cells of the 
islets of Langerhans in the pancreas. It was discovered with the contributions of 
Frederick Grant Banting, Charles Best, James Collip, and J.J.R. Macleod, in 1922. 
Insulin binds to the insulin receptor (INSR) inducing translocation of glucose 
transporters to the plasma membrane and allowing glucose transport to the cell 
(Schulingkamp 2000) (Fig 10). Cell sensitivity impairment to insulin reduces glucose 
uptake, which results increase in blood glucose (Wilcox 2005). This abnormal event 
is known as insulin resistance and it is characteristic in type 2 diabetes (Lin 2010). A 
previous report showed insulin sensitivity and insulin secretion impairment in 
normoglycemic SCA1 patients. In this study, twelve SCA1 untreated and unrelated 
patients were analyzed revealing insulin secretion impairment, as well as 
simultaneous decrease in insulin sensitivity (Lalić 2010). 
Figure 10. Ef fect o f insu l in  on glucose uptake and g lucose metabolism. 
Insulin molecule(s) binds to the insulin receptor (INSR) (1), which is activated. Activation of 
INSR can result in translocation of glucose transporter (Glut) to the membrane surface (2) 
and mediation of glucose entry into the cell (3). Glucose is metabolized to pyruvate by 
glycolysis (4). Pyruvate can supply energy to living cells through the TCA when oxygen is 
present (aerobic respiration) in the mitochondria (5). Alternatively pyruvate ferments to 
produce lactate when oxygen is absent (fermentation) in the cytoplasm (6). TCA, citric acid 
cycle, also known as the tricarboxylic acid. (Schulingkamp 2000), (Bolaños 2010) (Wilcox 
2005) 
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The insulin receptor (INSR) is a member of the ligand-activated receptor and 
tyrosine kinase family of transmembrane signaling proteins. INSR is a dimer 
consisting of two α subunits that contain the site for insulin binding, and two β units 
where the tyrosine kinase domain is localized. The principal physiological role of the 
INSR seems to be metabolic regulation, whereas all other receptor tyrosine kinases 
are involved in other pathways such as regulation of cell growth and differentiation 
(Lee 1994).  
 
The activation of INSR triggers the translocation of glucose transporter to the 
membrane that mediates the facilitated influx of glucose (Schulingkamp 2000) (Fig 
10). Most glucose transporters belong to the GLUT (SLC2A) family of lipid bilayer 
membrane transport proteins. In humans, fourteen GLUT proteins have been 
identified. They can transport other metabolites besides glucose, such as fructose, 
myoinositol, vitamins and urate (Thorens 2010). GLUT1-GLUT4 transporters are the 
well-characterized glucose transporter isoforms. 
 
• GLUT1 (SLC2A1): It is expressed at highest levels in the endothelial cells of 
blood–brain barrier tissue in human adults, supplying glucose to the cells of the 
central nervous system (Takata 1990). GLUT1 is normally upregulated in high 
sugar demanding tissues such as cancer tumors (Ganapathy 2009). 
• GLUT2 (SLC2A2): It is the principal transporter to transfer glucose between liver 
and blood. It is also expressed in intestine and pancreas (Thorens 1992). 
• GLUT3 (SLC2A3): It is the most important glucose transporter in neuronal 
tissue. It is localized in both dendrites and axons. Its expression level in different 
regions of the brain correlates with regional cerebral glucose utilization (Simpson 
2008). 
• GLUT4 (SLC2A4): The principal glucose transporter protein that mediates 
glucose uptake after the food ingestion is GLUT4 (Huang 2007). It is mainly 
present in skeletal, adipose and cardiac muscle, but it also localizes in some 
brain regions as hippocampus (Huang 2007, Patel 2014).  
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1.4.2. Glycolysis 
 
The elucidation of the glycolytic pathway started in 1860 with Louis Pasteur 
observing that microorganisms were responsible for fermentation. By 1940 the 
complete glycolytic pathway was elucidated by the combined efforts of several 
scientists including Otto Fritz Meyerhof (Kresge 2005). 
 
Glycolysis (from glycose-, an older term for glucose, and -lysis degradation) 
is the metabolic pathway that oxidizes glucose into pyruvate for the energy 
obtaining. The energy released in this process is used to form the high-energy 
compounds ATP (adenosine triphosphate) and NADH (reduced nicotinamide 
adenine dinucleotide) (Bolaños 2010, Pelicano 2006) (Fig 11).  
 
Glycolysis process occurs in the cytoplasm and does not use molecular 
oxygen for any of its reactions. However, glycolysis products can follow different 
paths to be processed. When molecular oxygen is used in the disposal of the 
products of glycolysis, the process is usually said to be aerobic, while if the disposal 
does not use oxygen, the process is referred to be anaerobic (Bolaños 2010, Li 
2015).  
 
Glycolysis includes 10 reactions and can be divided in two phases (Fig 11): 
 
v The Preparatory Phase or Investment Phase: In this stage ATP is consumed and 
includes the first five reactions. 
1. The first reaction is the phosphorylation of glucose to form glucose 6-
phosphate (G6P) catalyzed by a family of isoenzymes known as 
hexokinases (HKs). In mammalian four isoenzymes of hexokinase 
have been identified. HKs are allosterically inhibited by product 
accumulation (G-6-P). This reaction consumes ATP and is 
irreversible. This step helps to keep low glucose levels into the cell,  
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Figure 11. The metabolic pathway of glyco lys is.  Glycolysis converts glucose to 
pyruvate. Each chemical modification (red box) is performed by a different enzyme. 
Glycolysis can be separated in two phases: the preparatory phase and the pay-off phase. 
The preparatory phase has 5 reactions. ATP is consumed in the irreversible reactions 
number 1 and 3 (purple arrows).  In the reaction number 4, F1,6BP (6 molecules of 
carbon) is split in 2 molecules: GADP(3 molecules of carbon) and DHAP (3 molecule of 
carbon). The pay-off phase has 5 reactions. NADH is synthetized in the reaction number 6 
(green arrow). ATP is produced in the reactions number 7 and 10 (yellow arrows). The 
reaction number 10 is irreversible. Enzymes: HK, hexokinase, G6P, glucose-6-
phosphatase; PGI, phosphoglucose isomerase PFK, phosphofructokinase; ALDO, 
aldolase; DHAP, dihydroxyacetone phosphate; GAPD,	   glyceralde 3-phosphate; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; PGK, phosphoglycerate kinase; PGM, 
phosphoglycerate mutase; ENO, enolase; PK, pyruvate kinase. Metabolites: G6P, 
glucose-6-phosphato; F6P, fructose-6-phosphatase; F1,6BP, fructose-1,6-
biphosphatase; GADP, glyceralde 3-phosphate; DHAP, dihydroxyacetone phosphate; 
1,3PG, 1,3-biphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate, 
PEP, phosphoenolpyruvate; ATP, adenosine triphosphate; ADP, adenosine diphosphate; 
NAD+, nicotinamide adenine dinucleotide oxidized; NADH, nicotinamide adenine 
dinucleotide reduced. Draw modified from Thomas Shafee. 
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allowing for more glucose uptake. Furthermore, G6P cannot be 
transported out of the cell, since there are no G6P transporters on 
the membrane.  
2. G6P is interconverted into fructose 6-phosphate (F6P) by glucose 
phosphate isomerase (PGI). In addition, G6P can decarboxylated to 
form ribose-5- phosphate in a series of reactions known as pentose-
phosphate pathway.  
3. Phosphorylation of F6P to fructose-1,6-biphosphate (F1,6BP) 
catalyzed by the allosteric enzyme phosphofructokinase (PPK) using 
ATP as energy source. There are three phosphofructokinase genes in 
humans. This reaction is irreversible. 
4. The fourth reaction involves the breakdown of F1,6BP (6 carbons) 
into two triose sugars, glyceralde 3-phosphate (GADP) that is an 
aldose, and dihydroxyacetone phosphate (DHAP), which is a ketose. 
This reaction is catalyzed by the enzyme aldolase (ALDO). 
5. Glyceralde 3-phosphate (GADP) can be interconverted to 
dihydroxyacetone phosphate (DHAP) by enzyme triose phosphate 
isomerase (TPI).  
 
v The Pay-Off Phase: in this second stage, energy is produced either in the form 
of ATP or NADH+H+, which can be later converted to ATP in the mitochondria 
via electron transport chain (ETS). Since glucose is converted to two triose 
sugars in the preparatory phase, each reaction in the pay-off phase occurs 
twice per glucose molecule. This stage produces four ATP molecules and two 
NADH molecules and includes the last 5 reactions. 
6. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) converts 
GADP to 1,3-biphophoglycerate (1,3BPG). GAPDH is 
dehydrogenated and the hydrogen released is used to reduce NAD+, 
a hydrogen carrier, to give NADH + H+. 
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7. In the seventh reaction 1,3BPG is interconverted to 3-
phosphoglycerate (3PG) catalyzed by phosphoglycerate kinase (PGK) 
generating one ATP molecule. Two isoenzymes of PGK have been 
identified in mammals.  
8. This reaction includes the isomerization of 3PG to 2-
phosphoglycerate (2PG) catalyzed by the enzyme phosphoglycerate 
mutase (PGM) 
9. Enolase (ENO) catalyzes the conversion of 2-PG to 
phosphoenolpyruvate (PEP). Three major isoforms of ENO have been 
identified in mammals. 
10. The final reaction of the glycolysis involves the dephosphorylation of 
(PEP) to pyruvate (Pyr) by the enzyme pyruvate kinase (PK) generating 
one molecules of ATP. PK is allosterically activated by PEP and 
negatively regulated by ATP. This reaction is irreversible. 
(Berg 2002, Pelicano 2006, Bolaños 2010, Nelson 2012) 
 
The metabolic fate of pyruvate depends on the tissue and environmental 
conditions. When oxygen is present, Pyr is interconverted to acetyl-coenzyme A 
(acetyl-CoA) in the mitochondria, where it is fully oxidized to CO2 through the citric 
acid cycle, also known as tricarboxylic acid cycle (TCA) or Krebs cycle. This 
process is called aerobic respiration. However, when insufficient oxygen is available 
or any component of the mitochondrial respiratory chain is impaired, Pyr is 
converted to lactate coupled with an oxidation of NADH to NAD+ by the enzyme 
lactate dehydrogenase (LDH). This process is known as fermentation (Bolaños 
2010, Pelicano 2006). Glycolysis and lactic acid fermentation are much increased in 
cancer cells even if oxygen is plentiful. This pathogenic event is called Warburg 
effect and may be a consequence of an adaptation to low-oxygen environments 
within tumors, mitochondria impairment in cancer cells, or an effect associated with 
cell proliferation (Vander-Heiden 2009). 
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Interestingly, mass spectrometry analysis in SCA1154Q knock-in mice 
cerebellum showed a significant reduction of the glycolytic metabolite glucose-6-
phosphate compared to WT mice (Perroud 2013). This study suggests that 
glycolysis misregulation is induced by the pathogenic SCA1154Q in these mice. 
 
 
1.4.3. Glucose metabol ism in neurological disorders 
 
Caloric restriction (CR) is a dietary regimen that reduces calorie intake 
without incurring malnutrition or a reduction in essential nutrients such as vitamins 
and amino acids. CR has been proved to have a strong correlation with lifespan 
extension and to improve health by delaying the onset of age-related diseases 
including neurodegenerative diseases (Walford 1987, Weindruch 1988, Mair 2008). 
This phenomenon is conserved across phyla as shown in a variety of studies from 
unicellular organisms to primates (Schulz 2007, Colman 2014).  
 
The benefits associated with CR are mediated by multiple pathways 
including glycolysis (Schulz 2007, Yao 2011). Thus, to evaluate the implication of 
glycolysis in CR benefits, glycolysis inhibitors are often used instead of restrictive 
dietary regimen. 2-deoxy-D-glucose (2-DG) is a glucose analog compound, which 
has been used over years to inhibit glycolysis (Sols 1954, Combs 1986, Pelicano 
2006). 2-DG is uptaken by glucose transporters into the cell and is phosphorylated 
(2-DG-P) by hexokinase in the first step of the glycolysis. 2-DG-P cannot be further 
metabolized by phosphate isomerase and is therefore accumulated in the 
cytoplasm interfering with sugar metabolism by inhibiting glycolytic enzymes (Sols 
1954, Wick 1957, Chen 1992). 2-DG is widely used in anti-cancer treatments with 
the purpose to abolish Warburg effect and it is in clinical trial . In addition, 2-DG 
was also used in the context of aging studies. For example, downregulation of 
glycolysis using 2-DG extends life span in Caenorhabditis elegans by inducing 
mitochondrial respiration and increasing oxidative stress (Schulz 2007). In addition, 
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2DG reduces Aβ pathology in mouse model of Alzheimer’s Disease (AD) by 
maintaining mitochondrial bioenergetic function (Yao 2011). 2-DG was also 
employed in other studies to reduce ATP production, revealing the upregulation of 
the proteasome activity under low ATP levels conditions. This suggests that 2DG 
can be use as a new strategy to manipulate proteasome activity by altering ATP 
endogenous levels (Huang 2010) (Fig 12). 
 
Accumulation of misfolded proteins and aggregates are characteristic in 
numerous late-onset neurodegenerative diseases such as HD, SCA1, Parkinson’s 
disease (PD) and AD (DiFiglia 1997, Ross 1997, Lippens 2007, Gundersen 2010). 
Molecular chaperones and ubiquitin–proteasome system (UPS) are essential to 
maintain proteins in properly folded states. This machinery start to fail in aged cells 
(Ben-Zvi 2009). Proteostasis networks deteriorate as a function of time and make 
cells more vulnerable to proteotoxic events (Douglas 2010). Based on these 
observations, many researchers are investigating dietary restriction, or  glycolysis 
downregulation more specifically, as a target to delay the proteotoxic onset caused 
by different conformational disease proteins (Luchsinger 2002, Schulz 2007, 
Steinkraus 2008, Douglas 2010). 
 
Other studies established a link between glucose metabolism and 
autophagy (Rabinowitz 2010). Autophagy is a mechanism for degradation and 
recycling of cellular components such as proteins and organelles in lysosomes 
(Kaushik 2010). There are three types of autophagy: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) (Lee, 2009). 
Macroautophagy is a well-established process in which double-membraned 
structures called autophagosomes enclose cellular material and then fuse with 
lysosomes where the material is degraded (Yang 2010). Microautophagy is a non-
selective lysosomal degradative process where cytoplasmic cargo is invaginated 
into the lysosome lumen (Li 2012). In the case of CMA, proteins are targeted to 
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lysosomes where they are recognized by Hsc70 chaperone and then translocated 
into its lumen where they are degraded (Cuervo 2014). 
 
Initially, autophagy was described as an alternative source of energy when 
nutrients are limited. Low nutrient condition activates autophagy through AMPK-
mTORC1 signaling pathway inhibition (Rabinowitz 2010) (Fig 12). The mechanism of 
signal integration between glycolytic and TORC1/autophagy pathways has not 
been yet elucidated. A previous study suggests the participation of hexokinase II 
Figure 12. Downregu lation of  g lycolys is activates autophagy and 
proteasome activ ity. Glycolysis downregulation produces an inhibition of AMPK-
mTORC1 signaling pathway, thus autophagy is activated and then misfolded proteins can 
be degradated (Ravikumar 2004), (Rabinowitz 2010). Downregulation of glycolysis also 
leads a decreasing of ATP levels that trigger the activation on the proteasome, whose 
function is to degrade damaged proteins (Huang, 2010). Both mechanisms can potentially 
degrade ATXN1 mutated protein levels 
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(HK-II) in this process. It showed that HK-II binds to TORC1 through its TOS motif, 
decreasing TORC1 activity, and thereby positively regulates protective autophagy 
(Roberts 2014). 
 
New findings provide an association between autophagy and 
neurodegenerative processes. Several studies show an increase in 
neurodegenerative events when autophagy is impaired in mice neuronal cells 
(Komatsu 2006, Hara 2006). Other studies in AD and PD detected autophagy 
dysfunction leading to accumulation of aberrant proteins (Nixon 2007, Pan 2008). In 
the case of HD, activation of autophagy reduces toxicity caused by mutated 
huntingtin protein in fly and mouse models by attenuating huntingtin accumulation 
(Ravikumar 2004). A link between neurodegenerative pathology, glucose 
metabolism impairment, and autophagy alteration has not been assessed. 
 
 
 
  
	   51	  
 
 
 
 
 
 
 
 
 
 
 
OBJETIVES 	  	   	  
	   52	  
2. OBJETIVES 	  
 
A previous study revealed impairment in insulin sensitivity and insulin 
secretion in normoglycemic SCA1 (Lalić 2010). In addition, mass spectrometry 
analysis in SCA1154Q knock-in mice cerebellum showed a significant reduction of the 
glycolytic metabolite glucose-6-phosphate compared to WT mice (Perroud 2013).  
 
Glycolysis inhibition leads to ATP level reduction, upregulating proteasome 
activity (Huang, 2010). Other studies established a link between glucose 
metabolism and autophagy (Rabinowitz 2010). 
 
I hypothesize that SCA1 pathogenesis impairs glucose metabolism and may 
modulate ATXN1 protein levels. 
 
In order to test this, I have considered the following specific objectives: 
 
§ Study glucose uptake in SCA1 mice model using positron emission tomography 
– fludeoxyglucose F18. 
§ Transcriptomic analysis in SCA1 mice and fly models to study possible 
alterations in glucose metabolism genes expression profiling. 
§ Metabolomic analysis in SCA1 Drosophila model to study levels of glycolytic 
metabolites. 
§ To study genetic interactions, carry out a genetic screen in Drosophila of all 
genes encoding glycolysis enzymes for potential modifier genes of SCA1. 
Evaluate if transcriptional changes observed in RNA sequencing are deleterious 
or compensatory. 	  
§ Study if the potential modifiers found can modulate ATXN1 protein levels.	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3. MATERIALS AND METHODS 
 
3.1. Drosophi la kinase screen 
 
The previously characterized y,w,UAS-ATXN182Q(line-F7);GMR-GAL4 line 
(Fernandez-Funez 2000) were used for the screen. shRNA (Figure 13) and loss-of-
function alleles were obtained from the Vienna Drosophila RNAi Center 
(http://stockcenter.vdrc.at/control/main) and the Bloomington Drosophila Stock 
Center at University of Indiana (http://flystocks.bio.indiana.edu) repositories. 
Animals were crossed and kept at 25 °C for the test of retinal degeneration. 
 
For scanning electron microscopy (SEM) images, whole flies were 
dehydrated in ethanol, critical-point dried in a Blazers Union FL-9496 model, 
covered with silver and analyzed with the JEOL JSM 6100 microscope. For 
sections of adult fly eyes, adult heads (1 day of age) were fixed over-night in 85% 
ethanol, 5% acetic acid and 3.5% formaldehyde, followed by dehydration in ethanol 
and embedded in paraffin. Vertical sections of 10µm were made with Olympus Cut 
4055, and then stained with hematoxylin. They were analyzed with a Nikon 
Microphot FXA microscope.  
 
3.2. Drosophi la motor performance tests 
 
ATXN182Q flies were crossed with transgenic flies carrying glycolytic genes 
shRNA (Figure 13) or p-element loss of function mutations. They were monitored to 
evaluate the effect of glycolytic enzymes in the pathogenesis caused by ATXN182Q 
in flies. Flies were raised at 28.5 oC. Flies are transferred to vials containing new 
food every day. Fifteen age-matched virgin females were placed in a 35 cm clean 
vial and tapped down to the bottom. The number of flies that climbed up 9 cm in 
15 s was recorded with infrared detector. We repeated this ten consecutive times 
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and the average of the ten observations was plotted for each day as shown in the 
chart. Two replicates were tested in parallel for each genotype. ATXN1(82Q) was 
expressed in the nervous system using nrv2-GAL4 (y,w,UAS-ATXN1(82Q)(F7) nrv2-
GAL4). 
 
 
3.3. Preparation of Drosophi la protein lysates and immunoblot 
 
For the Western Blot I used eight fly heads per genotype at 25.5oC. Protein 
lysates were prepared in NuPAGE LDS sample buffer (Invitrogen), and then run in 
NuPAGE Novex 4-12% Bis-Tris Protein Gels, 1.0 mm, 10 well. The proteins are 
Figure 13. Mechanism of small ha irpin RNA  (shRNA).  shRNA is transcribed in 
the nucleus by polymerase. The product is processed by Drosha and exported from the 
nucleus by Exportin 5. This product is then processed by Dicer and loaded into the RNA-
induced silencing complex (RISC). The sense strand (passenger) is degraded and the 
antisense strand (guide) directs RISC to messenger RNA (mRNA) that has a 
complementary sequence. In the case of perfect complementarity, RISC cleaves the 
mRNA. In the case of imperfect complementarity, RISC represses translation of the 
mRNA. In both of these cases, shRNA leads to target gene silencing. I use flies that carry 
shRNA with UAS as a promoter, thus shRNA will be transcribed only in presence of GAL4. 
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transferred to a nitrocellulose membrane for 2 hours at 200 V. Primary antibodies 
used were 11NQ anti-ATXN1 rabbit (Neuromab) 1:2000 and anti-laminC mouse to 
detect the loading control (Developmental Studies Hybridoma Bank) 1:2000.  
 
 
3.4 Metabolomics analysis in f l ies. NMR 
 
Female mice aged 9 weeks were anesthetized using Isoflurane before cervical 
dislocation. Cerebellum and brain stem were extracted from the whole brain, 
dissected into ≈5mm slices and placed in individual 1.5 ml eppendorf tubes. Tissue 
samples were snap frozen in liquid nitrogen, weighed and stored at -80 oC until the 
analysis.  
 
Tissues were smashed briefly in eppendorfs tubes whilst frozen with single-used 
plastic pellets. 100 µl of ice-cold 1XPBS were added to the smashed tissue and 
further homogenized using a motorized hand pestle. A further 900 µl of ice-cold 
1XPBS were added to the homogenized tissue and mixed well. Samples were 
placed on dry ice and sent to the NMR facility at University of Houston for analysis. 
 
The aqueous extracts are obtained in 500 µL of reconstitution buffer with lmM TSP 
as an internal standard. The organic extracts are reconstituted in 500 µL of CDCl3 
with 0.03% TMS as an internal standard. The NMR acquisition then involves locking 
to the solvent and shimming to achieve optimal line-shape. Specific pulse-
sequences are applied depending on the experimental hypothesis. Typically, ID 1H 
NMR includes zgpr, noesyprld (for single solvent suppression) and lclpnf2 (for 
double-solvent suppression. Typical 2D NMR comprises COSY and TOCSY 
sequences. Hetero nuclear experiments include 1H-13C HSQC and HMBC 
sequences. The obtained data are analyzed and the set of metabolites is 
determined. In dubious cases, the specific metabolites can be validated by spike-in 
experiments. 
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3.5. Network analysis of modif iers 
 
Network analysis was performed using Ingenuity Pathway Analysis (IPA). IPA 
Downstream Effects Analysis predicts the expected increase or decrease of gene 
functions, based on the experimental data. Downstream Effects Analysis compiles 
information from the literature into the Ingenuity Ingenuity Knowledge Base. The 
analysis examines genes in the data that are known to perform certain functions, 
compares the genes’ direction of change to expectations derived from the 
literature, then issues a prediction for each function based on the direction of 
change. The direction of change is the gene expression in the experimental 
samples relative to a control. If the direction of change is: 
§ Consistent with the literature across most genes, IPA predicts that the function 
will increase in the experimental sample. 
§ Mostly inconsistent with the literature, IPA predicts that the function will 
decrease in the experimental sample. 
§ Not clear (there is no clear pattern related to the literature), IPA does not make a 
prediction. 
 
IPA uses the z-score algorithm to make predictions. The z-score algorithm is 
designed to reduce the chance that random data will generate significant 
predictions. The score is the negative log of the p-value derived from the Fisher’s 
Exact test.  
 
3.6. Transcriptomics analysis. RNA-sequencing 
 
The Institutional Animal Care and Use Committee approved all animal use 
protocols. ATXN1[82Q] (Burright 1995) mice and were housed and managed by 
Research Animal Resources under SPF conditions in an AAALAC-approved facility. 
Whole cerebellar RNA from three biological replicates for each genotype was 
isolated using TRIzol Reagent (Life Technologies) and then purification using 
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RNAeasy Kit following the manufacturer’s procedure (Qiagen). Purified RNA was 
tested for quality control, including quantification using fluorimetry (RiboGreen 
assay, Life Technologies) and RNA integrity assessed with capillary electrophoresis 
(Agilent BioAnalyzer 2100, Algilent Technologies, Inc.) generating an RNA integrity 
number (RIN). All submitted samples had greater than 1ug total mass and RINs 
greater than 8. Library creation was completed using oligo-dT purification of 
polyadenylated RNA, which was reverse transcribed to create cDNA. The cDNA 
was fragmented, blunt‐ended, and ligated to barcoded adaptors. The library was 
size selected to 320bp +/- 5% to produce average inserts of approximately 200bp, 
and size distribution validated using capillary electrophoresis and quantified using 
fluorimetry (PicoGreen, Life Technologies) and Q‐PCR. The libraries were then 
normalized, pooled and sequenced. Samples were sequenced on an Illumina GAIIX 
using a 76nt paired-end read strategy. 
 
Initial read quality was determined using FastQC to determine the following: 
basic statistics, per base sequence quality, per sequence quality scores, per base 
sequence content, per base GC content, per sequence GC content, per base N 
content, sequence length distribution, sequence duplication levels, overrepresented 
sequences, kmer content. Using the FastQC results, reads were trimmed to an 
acceptable length. Reads were processed to remove contaminating adapter 
sequences. All paired-end reads were correctly synchronized. 
 
Reads were aligned to the mouse reference genome (Illumina igenomes 
mm9) with Tophat by using mostly default parameters, except a Std. Dev for 
Distance between Mate Pairs of 60 and using a gene annotation model only looking 
for supplied junctions. Differential gene expression was determined with Cuffdiff 
using default parameters. Splicing analysis was completed using GSNAP and 
DEXseq by using most default parameters. Genes/introns with a q≤0.05 were 
considered significant.  
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3.7. MRI 
 
MR images were obtained using a Bruker Avance BioSpec Spectrometer with a 
21cm horizontal bore (Bruker BioSpin, Billerica, MA) and a 75mm resonator. A rapid 
acquisition with relaxation enhancement (RARE) scan with the following scan 
parameters: TE=11ms, TR3817.9ms, RARE factor=8, # of averages=2, Total scan 
time=4m4s344ms was used to obtain images of the entire brain (Fig 14).  
 
3.8. PET-FDG 
 
All PET and CT images were obtained using an undocked Inveon scanner (Siemens 
AG, Knoxville, TN). Mice were fasted for 4 hours prior to injection of 18F-FDG. Each 
animal received 340 μCi of radioisotope (Cyclotope, Houston, TX) via IV tail vein 
injections while awake. Blood glucose levels were also assessed prior to infusion 
with 18F-FDG. One-hour post-injection of radioisotope, mice were anesthetized 
with 2% isoflurane in oxygen and placed on the imaging bed. Breathing and body 
temperature were monitored and maintained using a BioVet animal monitoring 
system (BioVet, Newark, NJ). A CT scan was acquired containing 220 projections 
covering 220°, with a source-to-detector distance of 312.91 mm and source-to-
center of rotation (COR) distance of 183.92 mm. Each projection was 650 ms with 
x-ray tube voltage and current respectively at 80 kVp and 500 µA. The PET scan 
was reconstructed using OSEM3D reconstruction and registered to the CT scan. 
Mice were imaged for 5 minutes (CT) and 30 minutes (PET) starting one hour post-
injection of the radioisotope (Fig 14).  
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3.9. Υ - Counting 
 
Υ -Counter measurements were used to corroborate the 18F-FDG measurements 
using a Υ -Counter (Wizard 2 2480; PerkinElmer, Waltham, MA). Mouse brain tissue 
was harvested after PET-FDG imaging immediately post-imaging. The 18F-FDG 
radioactivity was counted specifically within the cortex, cerebellum and blood was 
Figure 14. Positron emission tomography (PET) – 	   magnetic resonance 
imaging (MRI). Fludeoxyglucose (FDG), a glucose analog with the positron-emitting 
radioactive isotope fluorine-18 (18F) is transported into cells through glucose transporters 
and it is converted by the enzyme hexokinase to FDG phosphorylated (FDG-P). FDG-P 
cannot undergo further in glycolysis and tends to accumulate in the cytoplasm. Since 
positron emission tomography (PET) only detects radioactivity emitted by 18F, we cannot 
distinguish the different brain regions, mice were also imaged using MRI with the objective 
to identify the cerebellum portion (delimited by a green line) in the image obtained by PET. 
Finally, images obtained by PET and MRI were overlapped to quantify radioactivity emitted 
by the cerebellum area. 
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measured and corrected for radionucleotide decay from time of injection, and also 
normalized to injected dose and tissue weight. Data was reported as % injection 
dose per gram.  
 
3.10. PET Image Analysis 
 
MRI brain scans were registered manually with the PET/CT images using Inveon 
Research Workplace (Siemens AG, Knoxville, TN). Once, this was done, the whole 
brain and cerebellum of each mouse was segmented into distinct regions of 
interests (ROI). These ROIs were then used to measure the uptake of radioisotope 
into each of the segmented parts of the brain.  
 
3.11. Statist ical analysis 
 
Western Blot: protein samples were run three independent times, and were 
normalized using LamC as loading control. P-value was calculated with Student’s t-
test (tails: 2, type: 1).  
 
Motor performance tests: two replicates were tested in parallel for each 
genotype and they were repeated twice. Statistical analysis was performed with 
Prism (GraphPad, La Jolla, CA). Each time point was analyzed using two-way 
ANOVA followed by two-way ANOVA followed by Sidak’s multiple comparison 
tests.  
 
PET and Υ – Counting: Voxel intensity is reported as the mean ± standard 
deviation. Statistical analysis was performed with Prism (GraphPad, La Jolla, CA). 
T-test was used to compare multiple means with statistical significance set at p < 
0.05.  
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4. RESULTS 
 
4.1. Decreased glucose import into the cerebel lum of ATXN182Q 
transgenic mice 
 
Glucose is absorbed into the bloodstream during digestion, travels along the 
circulatory system and crosses the brain blood barrier in order to supply energy to 
central nervous system cells. Glucose is imported into cells through transporters 
that are activated via insulin signaling and are localized in the plasma membrane,. A 
previous study revealed that in SCA1 patients, insulin sensitivity and insulin 
secretion are impaired (Lalić 2010). In addition, SCA1 model of ATXN1154Q knock-in 
mice showed a decrease in glucose-6 phosphate glycolysis metabolite (Perroud 
2013). I hypothesize that the expression of mutant ATXN1 causes an impairment of 
glucose import. 
 
The B05 transgenic mouse model expresses mutant human ATXN1 with 82 repeats 
in the cerebellum using the cerebellum Pcp2 promoter (Burright 1995). Thus, in 
principle, the cerebellum is the only brain region that is affected in these mice. To 
measure the level of glucose import by cerebellar cells I carried out positron 
emission tomography (PET) and magnetic resonance imaging (MRI) analysis in 14 
week-old B05 mice (Fig 15). These mice were injected with fludeoxyglucose (FDG), 
a glucose analog where the hydroxyl group at the 2' position in the glucose 
molecule is substituted with the positron-emitting radioactive isotope fluorine-18 
(18F). FDG is transported into cells through glucose transporters and is converted to 
phosphorylated FDG (FDG-P) by the enzyme hexokinase. FDG-P cannot proceed 
further in glycolysis and therefore accumulates in the cytoplasm. Since PET only 
detects radioactivity emitted by 18F, I cannot distinguish the different brain regions. 
Therefore, B05 mice were also imaged using MRI, which allow the identification of 
the cerebellum portion in the image obtained by PET (Fig 15). I tested the blood 
glucose levels before the PET imaging. All animals were normoglycemic and 
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showed similar glucose levels to WT mice. Analysis of the images obtained by PET 
revealed glucose import impairment in SCA1 transgenic mice, which suggest lower 
glucose level in cerebellar cells (Fig 15). 
 
To confirm this result, I carried out gamma counting analysis (Fig 15). I 
extracted the cerebellum and measured the radioactive emission of the whole 
organ using a gamma counter. The total radioactivity was lower in the cerebellum of 
SCA1 transgenic animals than that in WT, confirming the results from the PET 
analysis (Fig 15). 
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Figure 15. Positron emission tomography (PET) -  magnetic resonance 
imaging (MRI)  and gamma counting revea l glucose import impai rment in 
cerebel lum ATXN182Q transgen ic mice using f ludeoxyglucose F18 as a 
radioactive isotope. A-F show images obtained by (PET) overlapped with images 
obtained by (MRI) in axial (A and D), sagittal (B and E) and coronal (C and F) sections. A-C 
correspond to ATXN182Q transgenic (Tg) mice and D-F correspond to wild type (WT) mice. 
Cerebellum area is delimitated using a red line. I observe a decrease in radioactivity 
intensity signal in cerebellum of Tg compared WT mice. G graph shows radioactivity signal 
quantification normalized (whole brain – cerebellum) from PET-MRI revealing a decrease in 
fludeoxyglucose F18 (FDG) signal in Tg compared WT mice cerebellum. H graph shows 
radioactivity signal quantification normalized (whole brain – cerebellum) from gamma 
counting and confirms a significantly lower level of FDG in the cerebellum of the Tg 
compared WT. (N=5, normalized: T-test, statistic: two-way ANOVA with multiple 
comparisons, **p<0.05, ***p<0.005) 
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4.2. Expression of glucose metabol ism genes is altered in SCA1 mice 
cerebel lum and SCA1 f l ies nervous system. 
 
Insulin activates insulin receptors, which leads to the activation of glucose 
transporters that allow the entry of glucose into cells where glucose is metabolized. 
Since MRI-PET studies suggested the impairment of glucose uptake, I investigated 
the possibility of altered expression of genes involved in glucose metabolism. RNA 
sequencing (RNAseq) was performed to analyze the transcriptomes of ATXN182Q 
transgenic mice (B05 mice) (at two different time points), ATXN154Q knock-in mice, 
and ATXN182Q transgenic flies. 
 
4.2.1. RNAseq in B05 ATXN182Q transgenic mice 
 
Total RNA was extracted from B05 and WT/FVB cerebellums. Since the 
disease shows a progression, I used two different time points to gain insight into 
the course of the disorder: five weeks of age, when animals show a mild 
phenotype; and twelve weeks of age, when the phenotype is much stronger.  
 
The RNAseq data of five-week old B05 mice showed an altered expression 
level of 336 transcripts, of which 33 (9.8% of total altered genes) are genes that 
participate in glucose metabolism (Fig 16). These data suggest an alteration in the 
expression pattern of glucose metabolism genes. Interestingly, Scl2a1, a glucose 
transporter showed a downregulation compared with the wild-type mice, which 
suggests an impairment in glucose uptake (Fig 17). I analyzed all transcripts that 
show an alteration using the informatics platform Ingenuity Pathways Analysis (IPA). 
IPA predicts the effect of gene expression changes in the dataset of biological 
processes. In this case I analyzed glucose uptake from the RNAseq data. This 
analysis did not predict any inhibition or activation of glucose uptake in B05 mice 
five-weeks old (Fig 16). However, it is important to note that IPA gives the same 
consideration to each gene that participates in a particular process. Thus, I should 
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perform further analysis for a more accurate result. For example, in this case Slc2a1 
glucose transporter gene transcript is downregulated, therefore it suggests a likely 
downregulation in glucose uptake process independent of the result obtained using 
IPA analysis. 
 
The RNAseq of twelve-week-old B05 mice showed altered expression in 
1493 genes, which is 4.5 times more than the number of gene expression changes 
in five-week old mice (Fig 16). This result is consistent with the progression of the 
disease severity. I found 133 (8.9% of total altered genes expression) altered gene 
expression level in glucose metabolism genes compared to WT mice (Fig 16). 
Furthermore, I found Slc2a13 glucose transporter, insulin receptor (InsR),  and 
some glycolytic enzymes (Hk2, AldoC, Gapdh, Eno1b and Pfkfb3 genes) were all 
downregulated, suggesting the decrease of glucose uptake and glycolytic flux (Fig 
17). I also performed IPA analysis and the results confirmed the glucose uptake 
inhibition (Fig 16).  
 
 
4.2.2. RNAseq in ATXN1154Q knock-in mice 
 
Total RNA was extracted from knockin and wild-type cerebellums in eight-
week old animals. I found 421 transcripts altered in KI mice compared with WT. 
Among those genes, I found 45 (10.5% of total altered genes) that are involved in 
glucose metabolism (Fig 16). I found that the expression levels of both Slc5a1, 
which is a sodium/glucose cotransporter, and ALDOC, which is a glycolytic enzyme 
were downregulated (Fig 17). These data suggest glucose metabolism 
dysregulation. I also performed IPA analysis and the result suggests that glucose 
uptake in the cerebellar cells in these animals was inhibited (Fig 16). This result 
agrees with data from the previous transcriptome analysis of B05 transgenic mice.  
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4.2.3. RNAseq in ATXN182Q transgenic flies 
 
Expression profiling in both transgenic and knock-in mice suggests a 
misregulation of glucose metabolism genes. To test if this phenomenon is 
conserved across phyla I examined the transcriptome of ATXN182Q transgenic flies.  
 
I used a pan-neuronal driver to express ATXN182Q in the Drosophila nervous 
system and I extracted total RNA from heads of 1-day-old flies. I found 359 
Drosophila transcripts genes altered in transgenic flies compared with wild-type 
flies, which correspond to 566 human homolog genes (Fig 16). From these 
transcripts, 53 (9.4% of total altered genes) genes are involved in glucose 
metabolism (Fig 16). I found that expression of pyruvate carboxylase (PC) and 
phosphoenolpyruvate carboxykinase 1 (PCK1) were upregulated. Interestingly both 
these enzymes play important roles in gluconeogenesis, to convert pyruvate into 
phosphoenolpyruvate (Fig 17). Thus, these data suggest misregulation of 
gluconeogenesis in SCA1 flies. IPA predicted inhibition of glucose uptake in 
neurons, which agrees with our finding in SCA1 mice (Fig 16). 
 
In summary, transcriptome analysis of SCA1 mice (transgenic and knock-in) 
and flies support the idea of impairment of glucose uptake and abnormal glucose 
metabolism during SCA1 pathogenesis. 
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A. MICE TG [ATXN182Q] – 5 weeks B. MICE TG [ATXN182Q] – 12 weeks 
D. FLY TG [ATXN182Q] – 1 day 
C. MICE KI [ATXN1154Q] – 8 weeks 
Figure 16. RNAseq revea ls an impairment o f g lucose uptake in neuronal 
cel ls  in both SCA1 mice (t ransgenic and knock- in )  and SCA1 f l ies. The table 
shows RNAseq results summary, number of transcripts altered in each model for 
carbohydrates metabolism and glucose uptake processes, and the Ingenuity Pathways 
Analysis (IPA) predicted scores of glucose uptake in cells. (A), there was no inhibition or 
activation of glucose intake in five-week old B05 transgenic mice; (B), (C) and (D), 
inhibition of glucose uptake was observed in twelve-week old B05 transgenic mice (B), 
eight-week old knock-in mice (C) and flies with one-day of age (D). IPA predicted scores 
are summarized in the table as highlighted. Driver: elav:GAL4. The negative log of the p-
value was derived from the Fisher’s Exact test. 
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Figure 17. Glucose metabol ism dysregu lation in SCA1 mice ( transgen ic and 
knock-in )  and f ly models revealed by RNAseq and NMR. Data obtained by 
RNAseq in SCA1 mice (transgenic and knock-in) show a downregulation in genes that 
participate in glucose uptake and glycolysis. RNAseq data of SCA1 transgenic flies 
showed an upregulation in enzymes that participate in gluconeogenesis. NMR analysis 
show reduced levels in glucose and pyruvate in SCA1 flies. G6P: glucose-6-phosphate, 
F6P: fructose-6-phosphate, F1,6P: fructose-1,6-biphosphate, GADP: glyceraldehyde 3-
phosphate, DHAP: dihydroxyacetone phosphate, 1,3PG: 1,3-bisphosphoglycerate, 3PG: 
3-phosphoglycerate, 2PG: 2- phosphoglycerate, PEP: phosphoenolpyruvate, SLC2A: 
Solute carrier family 2, facilitated glucose transporter, SLC5A: sodium-dependent glucose 
cotransporter, InsR: insulin receptor, PFKFB3: fructose-2,6-biphosphatase 3, HK2: 
hexokinase 2, G6PC: glucose-6-phosphatase, GPI: glucose-6-phosphate isomerase, 
PFK: phosphofructokinase, FBP: fructose-1,6-bisphosphatase, ALDOC: aldolase C, TPI: 
triosephosphate isomerase, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, PGK: 
phosphoglycerate kinase, PGAM: phosphoglycerate mutase, ENO1b: enolase 1b, PK: 
pyruvate kinase, LDHA/B: lactate dehydrogenase A/B, PDH: pyruvate dehydrogenase, 
PC: pyruvate carboxylase, PCK: phosphoenolpyruvate carboxykinase 1, TCA: tricarboxylic 
acid cycle. Figure shows human homologs. 
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4.3. Nuclear magnetic resonance spectroscopy reveals decreased 
levels of glucose and pyruvate in the nervous system of SCA1 
Drosophi la model 
 
In agreement with expression profiling studies, PET analysis showed 
impairment in glucose uptake in transgenic B05 and ATXN1154Q knock-in mice, as 
well as ATXN182Q flies. Moreover, a previous study showed a G6P reduction in 
ATXN1154Q knock-in mice revealed by mass spectrometry (Perroud 2013). Together 
these results suggest an alteration in glycolytic metabolites during SCA1 
pathogenesis. To test this hypothesis, I performed metabolomic profiling analysis.  
 
I carried out nuclear magnetic resonance (NMR) in transgenic files 
expressing ATXN182Q in the nervous system using elav:GAL4 pan-neuronal driver. 
NMR allows us to determine the abundance of certain glycolytic metabolites, based 
on the absorbance and re-emittion of molecules in a magnetic field. The peaks of 
Figure 18. Reduction o f glucose, pyruvate and maltose leve ls in ATXN182Q 
f l ies by NMR analys is .  Metabolomic characterization indicates the impairment of 
glucose and pyruvate (glycolysis), and maltose (tricarboxylic acid cycle) in flies that 
express ATXN182Q in the nervous system. Driver: elav:GAL4. No change was observed in 
lactate level. The estimated metabolites concentrations were quantified using Chenomx. 
*p<0.05.  
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nuclear magnetic resonance spectra, correspond to different metabolites. I found a 
decrease in glucose, pyruvate and maltose levels, suggesting impairment in sugar 
metabolism. I did not identify peaks that correspond to glycolysis intermediate 
metabolites. No difference was found in lactate levels (Fig 17, Fig 18).  
 
4.4. Suppression of neurodegeneration in the ret ina of SCA1 
Drosophi la model by reducing the activity of glycolyt ic genes  
 
I found glucose metabolism impairment using different approaches in SCA1 
mice and SCA1 flies. In addition, I reported a misregulation in glycolytic genes in 
SCA1 mice and reduction of glycolytic metabolites in SCA1 flies, suggesting 
impairment in glycolysis. The glycolysis pathway is the first process to metabolize 
glucose in cells after glucose import and it is a fundamental process in glucose 
metabolism. To evaluate whether the observed changes are due to pathogenic or 
compensatory events I assessed genetics interaction studies using our well-
characterized SCA1 Drosophila model. Expression of ATXN182Q transgene in the fly 
eyes (using gmr-GAL4) triggers retinal degeneration (Fig 19). To test if glycolytic 
pathway modulates mutant ATXN1-induced pathogenesis, I screened flies with 
knock-down of each glycolic gene in SCA1 flies. The retina structure was examined 
at 25oC to evaluate if reduction of the activity of glycolytic genes modifes the eye 
phenotype caused by ATXN182Q expression. 
For this purpose, I used existing mutations (shRNA and P-element loss of 
function) in Drosophila genes encoding glycolytic enzymes and crossed them with 
flies expressing the ATXN182Q transgene. I found that retinal degeneration induced 
by ATXN182Q was suppressed by knock-down of all the glycolytic genes tested. (Fig 
17, Fig 19). Thus, downregulation of glycolysis improves SCA1 induced retina 
degeneration.  
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Figure 19. Knock-down glycolys is genes suppressed SCA1 induced retina 
degenerat ion and improved photoreceptor  in tegri ty.  Images of paraffin sections 
of the retina. HEX: hexokinase, GPI: glucose-6-phosphate isomerase, PFK: 
phosphofructokinase, ALDO: aldolase, TPI: triosephosphate isomerase, GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase, PGK: phosphoglycerate kinase, PGM: 
phosphoglycerate mutase, ENO: enolase. shRNA: small hairpin RNA. LOF: loss of 
function alleles. TRiP: RNA interference. Driver: gmr:GAL4. Arrows indicate retina width.  
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4.5. Suppression of SCA1 behavioral def icits by knock-down of 
glycolyt ic genes in Drosophi la  
 
Downregulation of glycolytic genes reduced the toxicity caused by ATXN182Q 
expression in the fly retina. To validate these data I performed behavioral tests in 
flies. I expressed ATXN182Q in the nervous system using the nrv2–GAL4 pan-
neuronal driver. These flies show a reproducible and quantifiable motor 
performance impairment measured by percentage of ATXN182Q flies able to climb 
into plastic tubes compared with control flies carrying nrv2–GAL4 without the 
SCA182Q transgene. I crossed transgenic flies carrying glycolytic genes loss of 
function mutations with ATXN182Q flies. They were monitored to evaluate the effect 
of reduced glycolytic gene activity in motor impairments caused by ATXN182Q. 
 
I found 7 mutations (RNAi and P-element loss of function mutations) 
corresponding to 7 glycolytic genes (GPI, PFK, PGK, ALDO, TPI, GAPDH and PYK) 
that suppress ATXN182Q flies behavioral deficits (Fig 17, Fig 20). These results 
confirm the data obtained in ATXN182Q using the retinal neurodegeneration 
phenotype  and support the idea that downregulation of glycolysis leads decreased 
ATXN182Q toxicity in the SCA1 Drosophila model.  
 
In a few specific cases; ie., four RNAi constructs corresponding to glycolytic 
genes PGAM, GAPDH, PFK and ALDO, I found enhancement of the motor 
performance phenotype. For each of these four genes, additional alleles where 
tested in both behavioral and eye phenotype assay, and multiple alleles were 
identified that suppress ATXN182Q toxicity in both assays (Fig 19, Fig 20). These 
apparently contradictory results could arise from the different temperature used in 
each assay (25.5oC for eye and 28.5oC for motor-performance). Since UAS-GAL4 
system is temperature sensible, RNAi expression is higher at temperatures closer to 
30oC. Thus, an increase of the gene knock-down by these RNAi constructs may 
cause toxicity by excessive loss of function of the corresponding genes. 
	   75	   
Figure 20. Knock-down of genes involved in  glyco lys is suppresses 
behavioral deficits in  SCA1 Drosophi la model. Decreased levels in the fly 
homologs of GPI, PFK, PGK, ALDO, TPI, GAPDH and PYK suppress ATXN182Q-induced 
motor impairments. GPI: glucose-6-phosphate isomerase, PFK: phosphofructokinase, 
PGK: phosphoglycerate kinase, ALDOC aldolase C, TPI: triosephosphate isomerase, 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase, PYK: pyruvate kinase. shRNA: 
small hairpin RNA. LOF: loss of function alleles. Driver: nrv2:GAL4. Graph lines correspond 
to linear regressions from 2 replicates. Statistics: experimental compared to ATXN1[82Q] 
control, two-way ANOVA followed by multiple comparison tests *p<0.05, **p<0.005, 
***p<0.0005, ****p<0.0005.  
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4.6. Decrease of ATXN1 protein levels fol lowing knock-down of the 
glycolyt ic genes in Drosophi la 
 
Our data indicate that genetic inhibition of the glycolysis pathway 
suppresses ATXN182Q–induced retinal degeneration and behavioral deficits in flies. 
To gain insight into the mechanism by which ATXN182Q toxicity is suppressed I 
investigated the possibility that reducing the activity of glycolysis genes modulates 
ATXN182Q protein levels.  
 
I found that reducing levels of the Drosophila homologs of HEX, PGI, PFK, 
ALD, PGK, and GAPDH led to a decrease in ATXN182Q protein levels (Fig 17, Fig 
21). I investigated the possibility that these glycolysis genes exert their effects by 
modulating the UAS-GAL4 system. However, as shown in Fig 22, PFK knock-down 
does not impact expression of a GFP reporter from the UAS-GAL4 system. 
 
In contrast to the Western blots results described above, I found that loss of 
function of one specific allele (TPILOF16563) of the Drosophila homolog of TPI increases 
ATXN182Q levels (Fig 23). However, this allele worked as a suppressor in eye leading 
an increment in retinal thickness (Fig 23)., which suggests that ATXN182Q levels may 
increase because of the increment in the size of the rescued retina. This possibility 
will be investigated using a loading control responsive to amount of retinal tissue. 
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Figure 21. Knock-down of genes invo lved in glycolysis leads to a decrease 
of ATXN182Q prote in levels in  f l ies. Decreased levels of ATXN182Q protein induced by 
decreased levels of Drosophila homologues of the HEX, GPI, PFK, GAPDH, ALDO and 
PGK using shRNA by western blots (WB). Driver: gmr:GAL4. All WB were made in 
triplicate. Statistics: T- test *p<0.05, **p<0.005.  
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Figure 22. PFK knock-down decreases ATXN182Q prote in leve ls and does 
not impact expression of a GFP reporter f rom the UAS-GAL4 system. On the 
left, PFK loss of function allele increases ATXN1 protein levels. On the right, PFK loss of 
function allele does not impact in GFP protein levels. Measured by Western Blot. Driver: 
gmr:GAL4. All WB were made in triplicate. Statistic: T- test *p<0.05.  
 
Figure 23 Loss o f funct ion al le le of  the Drosophi la  homolog of TPI increases 
ATXN182Q prote in levels and suppresses eye retina phenotype. On the left, TPI 
loss of function allele increases ATXN1 protein levels measured by western blot. On the 
right, TPI loss of function allele suppresses retina eye phenotype caused by ATXN182Q 
expression. Driver: gmr:GAL4. WB was made in triplicate. Statistic: T- test *p<0.05.  
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5. DISCUSSION 
 
5.1. Analysis of glucose uptake in the central nervous systems of 
mouse and Drosophi la SCA1 models 
 
Previous studies pointed to decreased insulin sensitivity and insulin 
resistance in SCA1 patients (Lalić 2010). The activation of INSR triggers the 
translocation of glucose transporter to the membrane that mediates the facilitated 
influx of glucose (Schulingkamp 2000). Insulin resistance is defined where normal or 
elevated insulin level produce sensitivity impairment to insulin mediated glucose 
disposal (Wilcox 2005). Insulin resistance is often associated with a decrease in 
insulin-stimulated glucose import (Choi 2002). I hypothesize that SCA1 
pathogenesis causes glucose import impairment. To test this hypothesis, I 
performed gene expression profile and glucose import studies in SCA1 animal 
models.  
 
Expression of many genes changes as disease progresses in other 
neurodegenerative disorders (Dutta 2013, Saetre 2011). Since SCA1 is a 
progressive disorder, I studied gene expression profiles in the cerebellum of B05 
ATXN182Q transgenic mice at two different time points. Transcriptomic analyses 
using informatics approaches in younger transgenic animals [five week old, when 
first behavioral deficits emerge (Burright 1995)] do not show activation/inhibition in 
glucose uptake compared to wild-type mice (Fig 16). However, I observe a 
reduction in the expression of Slc2a1 gene, which is a glucose transporter (Fig 16, 
Fig 17). Slc2a1 is expressed at highest levels in the endothelial cells of blood–brain 
barrier tissue in human adults, supplying glucose to the cells of the central nervous 
system (Takata 1990). This suggests that glucose uptake is downregulated from 
early stages in B05 SCA1 transgenic mice. In the case of older transgenic mice [12 
week-old, when disease symptoms are more prominent (Burright 1995)], I found 
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4.5 times more glucose metabolism genes transcripts altered, compared with five-
week-old transgenic mice (Fig 16). Thus, the number of glucose metabolism genes 
misregulated in SCA1 transgenic animals appears to correlate with progression of 
disease pathogenesis. Bioinformatic analysis predicts inhibition of glucose uptake 
(Fig 16). In addition, I found reduced expression in the Slc2a13 and InsR genes (Fig 
16, Fig 17). Slc2a13 is a glucose transporter that is expressed in the cerebellum 
(Allen Mouse Brain Atlas). The InsR (insulin receptor) is activated by insulin, and then 
glucose transporters are translocated to the plasma membrane allowing glucose 
uptake (Schulingkamp 2000). In older (12-week-old) B05 ATXN182Q transgenic 
mice, I do not find downregulation of the expression of Slc2a1 transporter gene as 
observed in younger (5-week-old) B05 ATXN182Q transgenic mice. One possibility is 
that this difference is a consequence of the progression of the disease. 
 
B05 ATXN182Q transgenic mice express mutant ATXN1 protein only in 
Purkinje cells (Burright 1995). Thus, transgenic mice show only the phenotype 
associated with dysfunctional Purkinje cells. In principle, knock-in mice better 
recapitulate the normal spatial and temporal expression patterns at endogenous 
levels (Watase 2002). In addition, ATXN1154Q knock-in mice show a slower 
progression of the disease compared to B05 ATXN182Q transgenic mice (Watase 
2002). Therefore, I investigated the gene expression profile of ATXN1154Q knock-in 
mice at 8 weeks of age [mice already show behavioral deficits (Watase 2002)] to 
corroborate the results obtained with the transgenic one. In these mice I find that 
the expression level of Slc5a1, which is a sodium/glucose cotransporter, is 
downregulated, suggesting impairment in glucose import (Fig 16, Fig 17). Further, 
bioinformatic analysis predicts inhibition of glucose uptake (Fig 16). 
 
To study glucose import impairment in neuronal cells in vivo, I performed 
PET imaging in B05 ATXN182Q transgenic mice. These mice were injected with 
fludeoxyglucose (FDG), a glucose analog that contains a radioactive isotope. FDG is 
imported to cells through glucose transporters where is converted to FDG 
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phosphorylated (FDG-P) by hexokinase. FDG-P cannot proceed further in the 
glycolysis pathway and therefore it accumulates in the cytoplasm. Since these 
animals only express ATXN182Q transgene in the Purkinje cells (Burright 1995), I 
study glucose import in the cerebellum. Transgenic mice cerebella show a 
decrease in radioactive signal compared to wild-type animals (Fig 15). This result 
supports our hypotheses, that glucose uptake is downregulated in SCA1 transgenic 
mice cerebellar tissue. I also measured radioactive emission using a gamma 
counter in the mouse cerebellum. Gamma counting analysis revealed that 
transgenic mice cerebellums show lower radioactive signal than wild-type mice (Fig 
15).  
  
Taken together, these data from SCA1 mice supports the idea of glucose 
uptake impairment as a pathogenic mechanism in the SCA1 cerebellum.  
 
I also investigated if glucose metabolism is impaired in the Drosophila SCA1 
model, which expresses ATXN182Q in all neurons. Gene expression analysis  in 1-
day-old flies predicts inhibition in glucose uptake in agreement with the SCA1 
mouse data (Fig 16). No alterations were found in the expression of glucose 
transporters; however, glucose uptake in SCA1 flies may be impaired by another 
mechanism. Metabolomic (NMR) analysis in one-day-old flies expressing ATXN182Q 
in the nervous system reveals the reduction in glucose compared with wild-type 
flies (Fig 18). Glucose is the first substrate in the glycolytic pathway. I do not know if 
the glucose detected is intra or extracellular; therefore, I cannot conclude that 
glucose import is impaired in SCA1 flies. However I suggest that the pathogenesis 
induced by ATXN182Q causes glucose metabolism impairment in the Drosophila 
nervous system. 
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5.2. Analysis of glycolysis gene expression in mice and Drosophi la 
SCA1 models 
 
Previous reports established a connection between impairment in glucose 
transport and glycolytic flux inhibition (Choi 2002, Xin 2012). Therefore, I 
hypothesize that glucose uptake impairment leads glycolysis flux downregulation 
caused by SCA1. As described above, I sequenced the transcriptome of SCA1 
transgenic mice (two different time points), SCA1 knock-in mice, and SCA1 
transgenic flies.  
 
B05 ATXN182Q transgenic mice with five weeks of age do not show glycolytic 
genes transcripts altered. However, older transgenic mice (12 week-old) show 
reduced levels of Hk2, AldoC, Gapdh, Eno1b and Pfkfb3 transcripts Bioinformatic 
analysis predicts inhibition of glucose uptake (Fig 17). Hk2 shows a very low 
expression level in mice cerebellum (Allen Mouse Brain Atlas) in contrast to other 
hexokinases. Hk2 catalyzes the first glycolytic reactions, which is irreversible. The 
other 4 genes (AldoC, Gapdh, Eno1b and Pfkfb3) show mild/high expression levels 
in mice cerebellum (Allen Mouse Brain Atlas). AldoC, Gapdh and Eno1b enzymes 
catalyze the steps, four, six and nine respectively, which are reversible reactions 
(Berg, 2002). On the other hand, Pfkfb3 enzyme controls glycolytic flux by 
determining the intracellular concentration of fructose-2,6-bisphosphate, an 
allosteric activator of the glycolytic enzyme PFK (Van Schaftingen 1981, Yang 
2014). These data suggest that expression of glycolytic genes is progressively 
reduced in transgenic mice compared to wild type as disease progresses. 
 
Previous mass spectrometry analysis reported G6P reduction in 14-week-
old ATXN1154Q knock-in mice (Perroud 2013). G6P is produced by phosphorylation 
of glucose during the first step in the glycolysis pathway (Berg, 2002). This reaction 
is irreversible and is catalyzed by the enzyme hexokinase (Berg, 2002). This 
observation suggests a reduction of glycolysis in this mouse model.  
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RNA sequencing in 8-week-old ATXN1154Q knock-in mice show that AldoC 
glycolytic gene expression is reduced (Fig 17). AldoC was also found 
downregulated in B05 SCA182Q transgenic mice. Since reduction in G6P was found 
in older ATXN1154Q knock-in mice (14 weeks-old) it is possible that reduced 
expression of other glycolytic genes may occur at later stages. 
 
ATXN182Q transgenic flies do no show any glycolytic gene expression 
alterations compared to WT flies. However, I found that PC and PCK1 human 
homolog expression are upregulated in SCA1 flies compared to wild-type. PC and 
PCK1 are two enzymes that play important roles in gluconeogenesis regulating two 
irreversible steps of this process (Jitrapakdee 2008, Xiong 2011). Gluconeogenesis 
is a metabolic pathway that results in the generation of glucose from non-
carbohydrate carbon substrates such as pyruvate (Young 1977).  
 
As described previously, metabolomics (NMR) analysis revealed reduction in 
glucose, maltose and pyruvate levels in SCA1 flies. Maltose is a disaccharide 
formed from two units of glucose that can be hydrolyzed into monosaccharaides 
and then enter the glycolysis (Berg 2002). The lower glucose and maltose levels 
found in SCA1 flies suggest that neurons are in a starvation-like condition that leads 
to the upregulation of gluconeogenic genes expression in certain tissues including 
the brain (Rothman 1991). In agreement with this, I found that expression of PC and 
PCK1 are increased. Pyruvate can be synthesized from glucose through glycolysis, 
converted back to carbohydrates (such as glucose) via gluconeogenesis. In 
gluconeogenesis, PC converts pyruvate to oxaloacetate, and then oxaloacetate is 
converted to phosphoenolpyruvate by PCK1 (Young 1977). Pyruvate levels are 
found decreased in SCA1 flies compare to wild-type (Fig 18). I suggest that 
decreased levels of glucose trigger downregulation of glycolytic flux resulting in 
pyruvate levels reduction. Moreover, pyruvate conversion to oxaloacetate by PC is 
increased, suggesting a decrease in pyruvate levels.  
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Together these data from SCA1 flies suggest that ATXN182Q in flies leads to 
downregulation of glycolysis and, in turn, this induces upregulation of 
gluconeogenesis. 
 
 
5.3. Glycolysis as a modulator of SCA1 pathogenesis 
 
The data described above support the idea that SCA1 pathogenesis leads 
to impairment of glycolysis in both SCA1 transgenic mice and flies. To evaluate the 
role of glycolysis in the toxicity caused by ATXN182Q in flies, I screened SCA1 flies 
with a knock-down (shRNA) of each glycolic gene using retinal degeneration as a 
readout. To drive expression of the ATXN182Q and shRNAs to the eye, I used the 
Glass Multimer Reporter (GMR) gene promoter, which is widely expressed in 
photoreceptor cells from third instar larval stage (Yu 2010). 
 
 In mammals, glycolytic reactions are mediated by the products of two or 
more redundant genes, with the exception of the reaction where GAPD is 
converted to 1,3PG, which is catalyzed by Gapdh (Berg, 2002). Mutations in one of 
the redundant genes may have a smaller effect on the fitness of the organism than 
expected from the gene function (Ardell 2001). However, each glycolytic reaction in 
Drosophila is catalyzed by one enzyme. Curiously, I also find an exception in flies in 
the same reaction catalyzed by Gapdh (Sun 1988). For this reaction, Drosophila 
has two genes encoding glyceraldehyde-3-phosphate dehydrogenase, Gapdh-1 
and Gapdh-2. These two genes are highly expressed in larvae and late pupa, but 
not in adult, where the level of the Gapdh-1 transcript strongly decreases, whereas 
Gapdh-2 expression remains at a constant high level (Sun 1988). Therefore, using 
flies I minimize mechanisms that compensate for the loss of functional genetic 
information. 
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Although all these genes catalyze glycolytic reactions, only HK, PFK and 
PYK catalyze irreversible reactions. Consequently, each of them serves as a control 
site as well as catalytic roles (Berg 2002). The activities of these enzymes are 
regulated by covalent modification or by the reversible binding of allosteric effector. 
In addition, their amount is varied by the regulation of transcription (Berg, 2002). 
Here, I knockdown these genes using multiple “loss of function” mutations including 
shRNAs and P-elements inserted in genes locus disrupting its expression. shRNA 
Drosophila strains contain an inducible UAS-RNAi construct against a single 
protein-coding gene (http://stockcenter.vdrc.at.). I used shRNA transgene 
constructs that were selected for not having predicted off-targets 
(http://stockcenter.vdrc.at.). Thus, by means of these genetic tools that cause 
partial loss of function in the corresponding genes I expect to reduce the glycolytic 
flux.  
 
I found that the retinal degeneration induced by SCA1 82Q transgene is 
ameliorated by knock-down of all the glycolytic genes including HK, PFK and PYK 
human homologs (Fig 19). I cannot predict if the GPI, ALDO, TPI, GAPDH, PGK, 
PGAM, ENO knockdown mutations lead to decreased glycolysis since all of these 
enzymes catalyze reversible reactions. However, knocking-down the HK, PFK and 
PYK homologs, I suppress histopathological features induced by ATXN182Q in the fly 
retina. These enzymes catalyze irreversible glycolytic reactions, thus, the 
knockdown of these three genes would be expected to reduce the glycolytic flux.  
 
In conclusion, these data indicate that reducing glycolysis flux by knocking 
down glycolytic genes ameliorates toxicity induced by ATXN182Q in the Drosophila 
retina. 
 
Next, I evaluated the effect of knocking down glycolytic enzymes in the 
pathogenesis caused by ATXN182Q in the nervous system using behavioral a 
readout. I drive the ATXN182Q expression to the nervous system inducing motor 
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performance deficits. In this case, I use nervana 2 gene (nrv2) promoter, which is 
expressed in central and peripheral nervous system (Sun 1995, Sun 1998), to drive 
the ATXN182Q expression. This assay allows us to study the progression of the 
SCA1 pathology in flies nervous system caused by ATXN182Q.  
 
I use the same genetic tools (shRNA and P-elements insertions) that I used 
in the previous eye screen to induce partial loss of function of the corresponding 
genes in the nervous system. I found 7 mutations that correspond to 7 glycolytic 
genes (GPI, PFK, PGK, ALDO, TPI, GAPDH and PYK human homologs) that 
progressively improve the motor-performance phenotype showed by ATXN182Q flies 
(Fig 20). 
 
However, I found four UAS-RNAi corresponding to four glycolytic genes 
(PGAM, GAPDH, PFK and ALDO) that enhance ATXN182Q fly motor performance 
phenotype. One possibility is that these UAS-RNAi constructs cause excessive loss 
of function of the corresponding genes leading to toxicity. To test this possibility, I 
examined more alleles from these genes using the retina and behavioral 
phenotypes. I found alleles from all these genes that suppress retina degeneration, 
and alleles from all these genes, except PGAM, that suppress behavioral deficits 
(Fig 19, Fig 20). Nevertheless, further controls should be done to evaluate it, such 
as analyzing the motor-performance phenotype of these UAS-RNAi constructs  in a 
background with out the ATXN182Q  transgene expression. 
 
Together these data suggest that reducing the glycolysis flux improves the 
progressive behavioral deficits caused by ATXN182Q transgene expression in the  
Drosophila nervous system. 
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5.4. Mechanism to modulate of SCA1 pathogenesis 
 
Identifying targets that can modulate the steady-state levels of a disease-
causing protein is a key strategy to develop new therapeutic approaches since the 
severity of neurodegeneration in SCA1 correlates with the levels of the mutant 
ATXN1 protein. Proteasome and autophagy are two well-characterized 
mechanisms to reduce proteins levels (Kaushik 2010, Bhattacharyya 2014). 
Proteasome degrades damaged proteins by proteolysis and its impairment has 
been associated with SCA1 pathogenesis (Fernandez-Funez 2000, Bhattacharyya 
2014). Autophagy is a mechanism of degradation and recycling of cellular 
components including proteins and organelles (Kaushik 2010). In the context of HD, 
activation of autophagy reduces mutant huntingtin accumulation leading to reduced 
toxicity (Ravikumar 2004). Thus, data from other neurodegenerative diseases 
suggest the potential role of autophagy to reduce levels of polyglutamine proteins 
such as ATXN1. 
 
Low nutrient conditions lead to autophagy activation to generate energy 
through AMPK-mTORC1 signaling pathway inhibition (Rabinowitz 2010). 
Interestingly, a previous study showed that the inhibition of the glycolytic flux using 
the glycolysis inhibitor 2-DG leads to upregulation the proteasome activity under 
low ATP levels conditions (Huang 2010). 
 
Metabolomic (NMR) analysis shows lower glucose and maltose levels in 
SCA1 flies nervous system compared to wild-type controls (Fig 18). In addition, 
transcriptomic analysis suggests that gluconeogenesis enzymes are upregulated in 
the nervous system of SCA1 flies (Fig 17). These data suggest that expression of 
ATXN182Q in flies causes low nutrients-like condition. I hypothesize that SCA1 
pathology decreases glycolytic flux as a compensatory mechanism to activate the 
protein degradation machinery such as autophagy and proteasome. 
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To test this hypothesis I study ATXN1 steady-state levels in SCA1 transgenic 
flies when I knockdown glycolytic genes. I found that reducing levels of the of HEX, 
PGI, PFK, ALD, PGK, and GAPDH Drosophila homologs leads to decrease in 
ATXN1 protein levels (Fig 21). As I have previously described, HEX and PFK work 
as control sites in glycolysis (Berg, 2002).  
 
An exception is a TPI p-element LOF mutation increases ATXN182Q levels (Fig 
23). This mutation was also showed to suppress eye phenotype in SCA1 flies 
leading an increment in retina thickness (Fig 23). This suggests that ATXN182Q 
protein levels may increase due to the increment in the size of the retina. Additional 
experiments using a loading control that reflects retinal size will clarify this point. 
 
Future studies need to be done to evaluate if the glycolysis inhibition leads to 
reduce ATXN1 protein levels through the proteasome and/or autophagy activation.  
 
In addition, I will study if the inhibition of the glycolysis in SCA1 mice triggers 
a decrease in mutant ATXN1 protein levels. I can use multiple approaches to inhibit 
glycolysis including glycolytic inhibitors that cross the brain blood barrier such as 2-
DG. As well, I can decrease the glycolysis flux using transgenic mice that knock-
down / knock-out the expression on glycolytic genes. I will measure ATXN1 protein 
levels under glycolysis inhibition context. Further, I will perform behavioral test to 
study if the inhibition of the glycolysis in SCA1 mice leads to decrease toxicity 
caused by the expression of mutant ATXN1. 
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6. CONCLUSIONS 
 
 
v SCA1 pathogenesis causes glucose uptake impairment in SCA1 mice 
cerebellar cells. 
 
v SCA1 pathogenesis causes glucose metabolism impairment in the 
Drosophila nervous system. 
 
v Expression of glycolytic genes is progressively reduced in SCA1 transgenic 
mice compared to wild type as disease progresses. 
 
v Downregulation of glycolysis caused by the expression of ATXN182Q 
transgene in flies, in turn, induces upregulation of gluconeogenesis. 
 
v Knocking down glycolytic genes in Drosophila ameliorates 
neurodegeneration by reducing steady-state levels of mutant ATXN1 protein. 
 
 
 
 
Downregulat ion of glycolysis is a compensatory mechanism taking 
place in nervous system during SCA1 pathogenesis, suggesting new 
therapeutic approaches to decrease ATXN1 neurotoxicity 
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7. CONCLUSIONES 
 
 
v La patogenia de SCA1 causa deficiencias en el transporte de glucosa en 
células del cerebelo de ratones. 
 
v La patogenia de SCA1 causa deficiencias en el metabolismo de la glucosa 
en el sistema nervioso de Drosophila. 
 
v La expresión de las enzimas glicolíticas se encuentra reducida en ratones 
transgénicos de SCA1. Está reducción se produce de manera progresiva de 
acuerdo con la progresión de la enfermedad.  
 
v La disminución del flujo glicolítico por la expresión del transgen ATXN182Q en 
Drosophila induce el aumento de la gluconeogénesis. 
 
v La inhibición parcial de la glicólisis en Drosophila, suprime la toxicidad que 
causa SCA1 en la retina y mejora los déficits comportamentales causados 
por la expresión de ATXN182Q. 
 
v La disminución de la patogenia en Drosophila se debe a la reducción de los 
niveles de la proteína ATXN1.  
 
La inhibición de la gl icol isis es un mecanismo compensatorio que 
t iene lugar en el sistema nervioso como consecuencia de la patogenia 
de SCA1 	  abriendo la puerta a nuevos avances terapéuticos para 
disminuir la neurotoxicidad producida por ATXN1. 
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